Thursday, June 15, 2017 6:10:50 PM
Window of opportunity is still open for Adamis Pharmaceuticals in the $1.2B EpiPen market with their Epinephrine Pre-Filled Syringe product.
The improved EPI PFS design includes features that should allow it to achieve meaningful penetration in both non-retail and consumer markets.
Mylan’s EpiPen pricing and recall mess over the past year has government and consumers demanding that another viable choice be made available.
Adamis has a growing compounding pharmacy business, strong pipeline, increasing institutional ownership, and is fully funded for the next 9-12 months with recent $17M secondary.
Mid-June PDUFA for EPI PFS presents a strong potential catalyst for the stock.
https://seekingalpha.com/article/4078008-adamis-pharmaceuticals-strong-buy-huge-potential-catalyst
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM